A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis

Table 2

Excellent compliance versus less excellent compliance.

Treatment Group	Grazax+		Grazax−
	Memozax		Memozax
	N	(%)	N	(%)
Number of subjects	139		122
Primary analysis no.
N	113		99
Excellent compliance (≥90%)	90	(79%)	78	(78%)
Less excellent compliance (<90%)	23	(21%)	21	(22%)

N: Number of subjects; (%): Percent subjects.